Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 16, 2025—Roche announced FDA approval for the Ventana MET (SP44) RxDx assay, the first companion diagnostic approved to aid in determining MET protein expression in patients with non-small cell lung cancer. These patients may now be eligible for treatment with AbbVie’s c-Met targeted therapy Emrelis (telisotuzumab vedotin-tllv).
April 29, 2025—Roche announced that the FDA granted breakthrough device designation for the Ventana TROP2 (EPR20043) RxDx device, a computational pathology device.
March 2025—Roche unveiled a proprietary sequencing by expansion (SBX) technology that offers ultra-rapid, high-throughput sequencing that is flexible and scalable for a broad range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. The novel sequencing approach uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer.
Feb. 24, 2025—Roche unveiled a proprietary sequencing by expansion (SBX) technology that offers ultra-rapid, high-throughput sequencing that is flexible and scalable for a broad range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing.
Feb. 18, 2025—Roche announced that its Roche Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance.
Feb. 3, 2025—The Food and Drug Administration approved a label expansion for the Roche Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone-receptor-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with Enhertu.
Jan. 30, 2025—Roche announced that the Tina-quant Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the FDA.
Jan. 22, 2025—Roche announced that the FDA has granted 510(k) clearance and CLIA waiver for its Cobas Liat sexually transmitted infection multiplex assay panels.
Jan. 13, 2025—Roche announced that its whole slide imaging system, Roche Digital Pathology Dx, has received an additional 510(k) clearance from the FDA. This clearance modifies the one the company received in June 2024 for Roche Digital Pathology Dx, which includes the Ventana DP 200 slide scanner, Roche’s digital pathology workflow software and a display, and now adds the Ventana DP 600 slide scanner. The Ventana DP 600 has 40 times the capacity of the DP 200 and uses the
January 2025—Roche announced it has received CE mark approval for its Cobas Mass Spec solution, including the Cobas i 601 analyzer and Ionify reagent pack of four assays for steroid hormones. The CE mark is the first milestone in the global launch of the Cobas Mass Spec solution, Roche said in a press statement. Following the launch, the company will roll out a menu of more than 60 analytes for testing of steroid hormones, vitamin D metabolites, and immunosuppressant drugs, as well as for therapeutic drug monitoring and drugs of abuse testing.
